Zollinger-Ellison syndrome historical perspective
Jump to navigation
Jump to search
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome historical perspective On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome historical perspective |
|
Zollinger-Ellison syndrome historical perspective in the news |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome historical perspective |
Overview
In 1955, Zollinger and Ellison published their seminal paper on gastrinomas wherein the Zollinger-Ellison syndrome was discussed for the first time.
Historical Perspective
- In 1955, Zollinger and Ellison announced their concept about ulcerogenic islet cell tumor which caused marked ulcer diathesis due to gastric hyperacidity.[1]
- Dr. Robert M. Zollinger and Dr. Edwin H. Ellison announced their theory at the annual meeting of American Surgical Association in Philadelphia in April 1956.[2]
- This concept raised from clinical case of two women who presented with perforated jejunal ulcers accompanied with severe ulcer diathesis.
- One of the patients was a 36 year-old woman with past history of 8 years abdominal pain and diarrhea. A laparotomy revealed perforated jejunal ulcers with severe recurrent hemorrhage. Although she underwent two subtotal gastric resections, transabdominal vagotomy, and transthoracic vagotomy, her symptoms were constantly persistent. Finally she underwent total gastrectomy; however, she died due to anastomic leakage from the surgery. Her autopsy was in favor of non-beta pancreatic islet cell tumor.[3]
- The other patient was a 19 year-old woman with 2 years of upper abdominal pain. She underwent a surgery in July 1953 and was diagnosed with two perforated jejunal ulcers. A truncal vagotomy and a radical subtotal gastrectomy were performed in January 1954. This operation was called a dream operation for ulcers by Zollinger. Due to unsuccessful results of the operation, she had to go through radiation therapy to her stomach. Eventually, total gastrectomy was performed. The results described a non-beta islet cell carcinoma with lymph node metastasis.
- In 1956, Ben Eiseman of Denver, Colorado, presented the same experience with one of his patients and called the condition "Zollinger-Ellison syndrome".[4]
- Discovery of insulinoma in 1927 and malignant carcinoid syndrome in 1953, have exceeded the presentation and discovery of Zollinger-Ellison syndrome.[5][6]
- In the 1960s, gastrin was described to be involved in the pathogenesis of gastric hyperacidity by Dr. Lester.[7]
- Roderic Gregory and Hilda Tracy of Liverpool proved that gastrin is the cause of Zollinger-Ellison syndrome. [8]
- Radioimmunoassay was developed for assessment of gastrin level in 1967 and 1968.[9][10]
- Histamine-2 blocking drugs (H2) were introduced as the first effective medical therapy for Zollinger-Ellison syndrome in 1975.[11]
References
- ↑ Zollinger RM (1991). "[The history of the Zollinger-Ellison syndrome]". Ann Gastroenterol Hepatol (Paris). 27 (5): 223–6. PMID 1746876.
- ↑ ZOLLINGER RM, ELLISON EH (1955). "Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas". Ann Surg. 142 (4): 709–23, discussion, 724–8. PMC 1465210. PMID 13259432.
- ↑ Kaplan, Edwin L.; Tanaka, Reiko; Ito, Koichi; Younes, Nidal; Friesen, Stanley R. (1994). "The discovery of the Zollinger-Ellison syndrome". Journal of Hepato-Biliary-Pancreatic Surgery. 1 (5): 509–516. doi:10.1007/BF01211912. ISSN 0944-1166.
- ↑ Chey WY, Chang TM, Lee KY, Sun G, Kim CK, You CH; et al. (1989). "Ulcerogenic tumor syndrome of the pancreas associated with a nongastrin acid secretagogue". Ann Surg. 210 (2): 139–49. PMC 1357819. PMID 2757418.
- ↑ Wilder, Russell M.; Allan, Frank N.; Power, M. H.; Robertson, H. E. (1927). "CARCINOMA OF THE ISLANDS OF THE PANCREAS". Journal of the American Medical Association. 89 (5): 348. doi:10.1001/jama.1927.02690050014007. ISSN 0002-9955.
- ↑ Epelboym I, Mazeh H (2014). "Zollinger-Ellison syndrome: classical considerations and current controversies". Oncologist. 19 (1): 44–50. doi:10.1634/theoncologist.2013-0369. PMC 3903066. PMID 24319020.
- ↑ Hou W, Schubert ML (2006). "Gastric secretion". Curr Opin Gastroenterol. 22 (6): 593–8. doi:10.1097/01.mog.0000245538.43142.87. PMID 17053435.
- ↑ Leske JS (1985). "Hyperglycemic hyperosmolar nonketotic coma: a nursing care plan". Crit Care Nurse. 5 (5): 49–56. PMID 3851712.
- ↑ Stremple, JohnF.; Abramoff, Peter; Van Oss, CarelJ.; Wilson, StuartD.; Ellison, EdwinH. (1967). "ANTIBODIES TO SYNTHETIC HUMAN GASTRIN I". The Lancet. 290 (7527): 1180–1182. doi:10.1016/S0140-6736(67)91895-8. ISSN 0140-6736.
- ↑ McGuigan, James E.; Trudeau, Walter L. (1968). "Immunochemical Measurement of Elevated Levels of Gastrin in the Serum of Patients with Pancreatic Tumors of the Zollinger-Ellison Variety". New England Journal of Medicine. 278 (24): 1308–1313. doi:10.1056/NEJM196806132782402. ISSN 0028-4793.
- ↑ Mainardi M, Maxwell V, Sturdevant RA, Isenberg JI (1975). "Inhibition of gastric acid secretion by metiamide in Zollinger-Ellison syndrome". Am J Dig Dis. 20 (3): 280–1. PMID 1124750.